Related Experiment Videos
Drug-induced pancreatitis: an update.
Chirag D Trivedi1, C S Pitchumoni
1Department of Medicine, Robert Wood Johnson Medical School, and Division of Gastroenterology, Hepatology and Clinical Nutrition, St. Peter's University Hospital, New Brunswick, NJ 08901, USA.
Journal of Clinical Gastroenterology
|August 6, 2005
Summary
Drug-induced pancreatitis (DIP) is an underrecognized adverse drug reaction. Many common medications are linked to DIP, necessitating a high index of suspicion in at-risk patients.
Area of Science:
- Gastroenterology
- Pharmacology
- Clinical Medicine
Background:
- Drug-induced pancreatitis (DIP) is a frequently overlooked adverse drug event.
- Identifying specific causative medications is challenging due to diagnostic difficulties.
Purpose of the Study:
- To highlight the problem of drug-induced pancreatitis (DIP).
- To classify medications associated with acute pancreatitis (AP) based on evidence strength.
- To review the association of top-prescribed medications with AP.
Main Methods:
- Conducted a literature search of DIP cases from 1966 to 2004.
- Classified implicated medications into three classes based on reported cases and reexposure.
- Analyzed the association of the top 100 most frequently prescribed US medications with AP.
Main Results:
- Identified 44 of the top 100 US prescription medications implicated in AP.
- Class I drugs (≥20 cases, documented reexposure) include didanosine, azathioprine, and valproic acid.
- Class II drugs (>10 cases) include acetaminophen, enalapril, and hydrochlorothiazide.
Conclusions:
- Physicians should maintain a high suspicion for DIP, especially in certain patient groups.
- At-risk populations include geriatric patients, HIV+ individuals, cancer patients, and those on immunomodulators.
- Early recognition and diagnosis of DIP are crucial for patient management.